培美曲塞联合顺铂治疗一线方案失败的晚期乳腺癌的疗效及安全性分析

Efficacy and Safety of Pemetrexed Combined with Cisplatin for Advanced Breast Cancer that Failed First-line Chemotherapy

目的探究培美曲塞联合顺铂对一线方案治疗失败的晚期乳腺癌患者的疗效及安全性。方法对一线乳腺癌治疗方案失败的晚期乳腺癌女性患者82例,给予培美曲塞联合顺铂治疗。两个治疗周期后依RECIST1.0标准评价疗效;WHO标准评价不良反应;Kaplan-Meier方法分析患者12个月生存函数。结果 82例患者均完成2个以上疗程的化疗,治疗有效率为40.24%,疾病控制率为70.73%;不良反应主要有血小板减少、恶心呕吐和皮疹等,Ⅲ、Ⅳ级不良反应发生率较低;1年生存率为54.88%。结论美曲塞联合顺铂对一线方案治疗失败的晚期乳腺癌有较好的疗效。

Objective To explore the efficacy and safety of pemetrexed combined with cisplatin for advanced breast cancer that failed first-line chemotherapy. Methods 82 female patients with advanced breast cancer who failed first-line chemotherapy were given pemetrexed combined with cisplatin. After 2 cycles of chemotherapy,efficacy was analyzed by RECIST1. 0,adverse reactions was analyzed by WHO,and 12-months survival function was analyzed by Kaplan-Meier method. Results All the82 patients had completed more than 2 cycles of chemotherapy. The effective rate was 40. 24% and the disease control rate was70. 73%. The main adverse reactions were thrombocytopenia,nausea and vomiting,and skin rashes. Ⅲ to Ⅳ levels of adverse reactions were at low incidence. 1-year survival rate was 54. 88%. Conclusion Pemetrexed combined with cisplatin for advanced breast cancer that failed first-line chemotherapy is effective and well tolerated.